AstraZeneca and FibroGens roxadustat, not yet filed in U.S., nabs 2nd anemia nod in China
By, Admin1 min read
Share
FibroGen has not even filed its AstraZeneca-partnered oral anemia drug roxadustat for U.S. approval. But the collaborators have already scored their second nod for the blockbuster hopeful in China
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.